EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
By J. Smolen, R. Landewé, J. Bijlsma, G. Burmester, K. Chatzidionysiou, M. Dougados, J. Nam, S. Ramiro, M. Voshaar, R. V. van Vollenhoven and 39 more. Annals of the Rheumatic Diseases, 2010
2,684 citations recorded by the source corpus.
Subfields: Hematology, Immunology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/fb0f9798782fc19973617b98d15c635e17b6630f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Rheumatology
Citations in the corpus
- Diagnosis and Management of Rheumatoid Arthritis: A Review (2018, positive): “If all conventional synthetic DMARDs are poorly tolerated or contraindicated, then IL-6R antibodies and JAK inhibitors are more efficacious than other agents.(69)”